Related references
Note: Only part of the references are listed.DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors
Nisha Pillay et al.
CANCER CELL (2019)
PARP inhibitors in ovarian cancer
Elisena Franzese et al.
CANCER TREATMENT REVIEWS (2019)
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Patrick G. Pilie et al.
CLINICAL CANCER RESEARCH (2019)
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
Roman M. Chabanon et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Panagiotis A. Konstantinopoulos et al.
LANCET ONCOLOGY (2019)
The multiple mechanisms that regulate p53 activity and cell fate
Antonina Hafner et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
The influence of BRCA2 mutation on localized prostate cancer
Renea A. Taylor et al.
NATURE REVIEWS UROLOGY (2019)
NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression
Chunjing Bian et al.
NATURE COMMUNICATIONS (2019)
Mitotic functions of poly(ADP-ribose) polymerases
Dea Slade
BIOCHEMICAL PHARMACOLOGY (2019)
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N. Moore et al.
LANCET ONCOLOGY (2019)
Targeting dePARylation selectively suppresses DNA repair-defective and PARP inhibitor-resistant malignancies
Shih-Hsun Chen et al.
SCIENCE ADVANCES (2019)
PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
Man Yee T. Keung et al.
JOURNAL OF CLINICAL MEDICINE (2019)
A decade of clinical development of PARP inhibitors in perspective
J. Mateo et al.
ANNALS OF ONCOLOGY (2019)
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
Yong Fang et al.
CANCER CELL (2019)
Activation of PARP-1 by snoRNAs Controls Ribosome Biogenesis and Cell Growth via the RNA Helicase DDX21
Dae-Seok Kim et al.
MOLECULAR CELL (2019)
PARP inhibition - opportunities in pancreatic cancer
Shubham Pant et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage
Sara Giovannini et al.
NUCLEIC ACIDS RESEARCH (2019)
Perspectives on PARPs in S Phase
Hana Hanzlikova et al.
TRENDS IN GENETICS (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
R. L. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
Mansoor Raza Mirza et al.
LANCET ONCOLOGY (2019)
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
Sylvie M. Noordermeer et al.
TRENDS IN CELL BIOLOGY (2019)
Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors
Marco Barazas et al.
CANCER RESEARCH (2019)
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
Jianfeng Shen et al.
CANCER RESEARCH (2019)
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)
Nicholas C. Turner et al.
CLINICAL CANCER RESEARCH (2019)
The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers
Antonio Marzio et al.
MOLECULAR CELL (2019)
State-of-the-art strategies for targeting the DNA damage response in cancer
Patrick G. Pilie et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kevin K. Lin et al.
CANCER DISCOVERY (2019)
Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death
Jerry H. Houl et al.
NATURE COMMUNICATIONS (2019)
Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity
Pingping Fang et al.
COMMUNICATIONS BIOLOGY (2019)
PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors
Leslie A. Parsels et al.
MOLECULAR CANCER RESEARCH (2018)
EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer
H. Yamaguchi et al.
ONCOGENE (2018)
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
C. Cruz et al.
ANNALS OF ONCOLOGY (2018)
Latest clinical evidence and further development of PARP inhibitors in ovarian cancer
M. R. Mirza et al.
ANNALS OF ONCOLOGY (2018)
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
Chaoyang Sun et al.
CANCER CELL (2018)
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
Ewa Gogola et al.
CANCER CELL (2018)
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
Yi-Mi Wu et al.
CELL (2018)
DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity
Rajat Gupta et al.
CELL (2018)
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
Lorenzo Galluzzi et al.
CELL DEATH AND DIFFERENTIATION (2018)
Reactive Oxygen Species in Metabolic and Inflammatory Signaling
Steven J. Forrester et al.
CIRCULATION RESEARCH (2018)
Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors
Sai-Wen Tang et al.
CLINICAL CANCER RESEARCH (2018)
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer
Alice Lallo et al.
CLINICAL CANCER RESEARCH (2018)
Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts
James H. Laird et al.
CLINICAL CANCER RESEARCH (2018)
Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib
Polly Gravells et al.
DNA REPAIR (2018)
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma
Maeve A. Lowery et al.
EUROPEAN JOURNAL OF CANCER (2018)
Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma
Sarah S. Bernards et al.
GYNECOLOGIC ONCOLOGY (2018)
The evolving landscape of predictive biomarkers of response to PARP inhibitors
Anish Thomas et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
M. Catherine Pietanza et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint
Xiaoting Lin et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
Noel Clarke et al.
LANCET ONCOLOGY (2018)
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl et al.
LANCET ONCOLOGY (2018)
SLFN11 Blocks Stressed Replication Forks Independently of ATR
Junko Murai et al.
MOLECULAR CELL (2018)
The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication
Hana Hanzlikova et al.
MOLECULAR CELL (2018)
Mutational game changer: Chromothripsis and its emerging relevance to cancer
Monique Nicole Helena Luijten et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2018)
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
Harveer Dev et al.
NATURE CELL BIOLOGY (2018)
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt et al.
NATURE MEDICINE (2018)
Super-resolution imaging identifies PARP1 and the Ku complex acting as DNA double-strand break sensors
Guang Yang et al.
NUCLEIC ACIDS RESEARCH (2018)
PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation
George E. Ronson et al.
NATURE COMMUNICATIONS (2018)
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
Stephen J. Pettitt et al.
NATURE COMMUNICATIONS (2018)
Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance
Jone Michelena et al.
NATURE COMMUNICATIONS (2018)
Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling into Place
Panagiotis Kotsantis et al.
CANCER DISCOVERY (2018)
Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas
Khyati Meghani et al.
CELL REPORTS (2018)
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells
Marco Barazas et al.
CELL REPORTS (2018)
Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer
Dong Hou et al.
REDOX BIOLOGY (2018)
AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations
Xiangbing Meng et al.
CANCERS (2018)
Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition
Brittany Haynes et al.
CANCER TREATMENT REVIEWS (2018)
Preserving replication fork integrity and competence via the homologous recombination pathway
Anissia Ait Saada et al.
DNA REPAIR (2018)
High speed of fork progression induces DNA replication stress and genomic instability
Apolinar Maya-Mendoza et al.
NATURE (2018)
CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions
Michal Zimmermann et al.
NATURE (2018)
53BP1 cooperation with the REV7-shieldin complex underpins DNA structure-specific NHEJ
Hind Ghezraoui et al.
NATURE (2018)
Intragenic origins due to short G1 phases underlie oncogene-induced DNA replication stress
Morgane Macheret et al.
NATURE (2018)
The shieldin complex mediates 53BP1-dependent DNA repair
Sylvie M. Noordermeer et al.
NATURE (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
Olga Kondrashova et al.
NATURE COMMUNICATIONS (2018)
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Marta Castroviejo-Bermejo et al.
EMBO MOLECULAR MEDICINE (2018)
PARP-1 regulates DNA repair factor availability
Matthew J. Schiewer et al.
EMBO MOLECULAR MEDICINE (2018)
CDK12 regulates DNA repair genes by suppressing intronic polyadenylation
Sara J. Dubbury et al.
NATURE (2018)
DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells
Yizhou Joseph He et al.
NATURE (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
Liya Ding et al.
CELL REPORTS (2018)
Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types
Arielle L. Heeke et al.
JCO PRECISION ONCOLOGY (2018)
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Rachna T. Shroff et al.
JCO PRECISION ONCOLOGY (2018)
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer
Jason. P. W. Carey et al.
CANCER RESEARCH (2018)
Targeting DNA damage repair in small cell lung cancer and the biomarker landscape
Triparna Sen et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer
Yajing Liu et al.
CLINICAL CANCER RESEARCH (2017)
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Benjamin H. Lok et al.
CLINICAL CANCER RESEARCH (2017)
Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models
Hyoung Kim et al.
CLINICAL CANCER RESEARCH (2017)
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
Ann-Gerd Thorsell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
Eileen E. Parkes et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
Eileen E. Parkes et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
Stephanie A. Yazinski et al.
GENES & DEVELOPMENT (2017)
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
Amit M. Oza et al.
GYNECOLOGIC ONCOLOGY (2017)
Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition
Stephanie Lheureux et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer
Elizabeth L. Christie et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al.
LANCET ONCOLOGY (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
Yung-Jue Bang et al.
LANCET ONCOLOGY (2017)
Replication Catastrophe: When a Checkpoint Fails because of Exhaustion
Luis Toledo et al.
MOLECULAR CELL (2017)
Restoration of Replication Fork Stability in BRCA1-and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers
Angelo Taglialatela et al.
MOLECULAR CELL (2017)
Integrative clinical genomics of metastatic cancer
Dan R. Robinson et al.
NATURE (2017)
cGAS surveillance of micronuclei links genome instability to innate immunity
Karen J. Mackenzie et al.
NATURE (2017)
Mitotic progression following DNA damage enables pattern recognition within micronuclei
Shane M. Harding et al.
NATURE (2017)
EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
Beatrice Rondinelli et al.
NATURE CELL BIOLOGY (2017)
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer
Paz Polak et al.
NATURE GENETICS (2017)
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Helen Davies et al.
NATURE MEDICINE (2017)
Non-homologous DNA end joining and alternative pathways to double-strand break repair
Howard H. Y. Chang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Arnab Ray Chaudhuri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A novel non-canonical PIP-box mediates PARG interaction with PCNA
Tanja Kaufmann et al.
NUCLEIC ACIDS RESEARCH (2017)
PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma
V. Colicchia et al.
ONCOGENE (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Androgen receptor inhibitor-induced BRCAness and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
Likun Li et al.
SCIENCE SIGNALING (2017)
Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition
Lu Yang et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Expanding functions of ADP-ribosylation in the maintenance of genome integrity
K. Martin-Hernandez et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2017)
Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
Mohammad Asim et al.
NATURE COMMUNICATIONS (2017)
Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells
Pepijn M. Schoonen et al.
NATURE COMMUNICATIONS (2017)
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Johann de Bono et al.
CANCER DISCOVERY (2017)
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Olga Kondrashova et al.
CANCER DISCOVERY (2017)
Analysis of Circulating Cell-Free DnA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
David Quigley et al.
CANCER DISCOVERY (2017)
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Jane Goodall et al.
CANCER DISCOVERY (2017)
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer
C. Allison Stewart et al.
ONCOTARGET (2017)
PARP inhibition causes premature loss of cohesion in cancer cells
Eva Kukolj et al.
ONCOTARGET (2017)
BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
Sergey Karakashev et al.
CELL REPORTS (2017)
Androgen receptor inhibitor-induced BRCAness and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
Likun Li et al.
SCIENCE SIGNALING (2017)
Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm
Daniel J. McGrail et al.
NPJ SYSTEMS BIOLOGY AND APPLICATIONS (2017)
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Britta Weigelt et al.
CLINICAL CANCER RESEARCH (2017)
Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
Charles-Andre Philip et al.
BMC CANCER (2017)
Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors
Saswati N. Chand et al.
CANCER RESEARCH (2017)
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
Stephanie Lheureux et al.
CLINICAL CANCER RESEARCH (2017)
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors
Rebecca Kristeleit et al.
CLINICAL CANCER RESEARCH (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells
Jenni Nikkilae et al.
BRITISH JOURNAL OF CANCER (2017)
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer
Michael J. Pishvaian et al.
BRITISH JOURNAL OF CANCER (2017)
Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase
Polly Gravells et al.
DNA REPAIR (2017)
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Eric E. Gardner et al.
CANCER CELL (2017)
Endogenous DNA Damage as a Source of Genomic Instability in Cancer
Anthony Tubbs et al.
CELL (2017)
mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer
Wei Mo et al.
CLINICAL CANCER RESEARCH (2016)
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent
Bing Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs
Vanesa Nogales et al.
ONCOTARGET (2016)
First-in-Class Chemical Probes against Poly(ADP-ribose) Glycohydrolase (PARG) Inhibit DNA Repair with Differential Pharmacology to Olaparib
Dominic I. James et al.
ACS CHEMICAL BIOLOGY (2016)
ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
Aparajitha Vaidyanathan et al.
BRITISH JOURNAL OF CANCER (2016)
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
Yvette Drew et al.
BRITISH JOURNAL OF CANCER (2016)
Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer
Nidal E. Muvarak et al.
CANCER CELL (2016)
PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency
Aurelia Noll et al.
CANCER CELL INTERNATIONAL (2016)
The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin
Yifan Wang et al.
CANCER RESEARCH (2016)
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Melinda L. Telli et al.
CLINICAL CANCER RESEARCH (2016)
PARP inhibitor combination therapy
Amy Drean et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes
Dong Wang et al.
GYNECOLOGIC ONCOLOGY (2016)
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1
Rinske Drost et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
Jonathan A. Ledermann et al.
LANCET ONCOLOGY (2016)
HELB Is a Feedback Inhibitor of DNA End Resection
Jan Tkac et al.
MOLECULAR CELL (2016)
Replication fork stability confers chemoresistance in BRCA-deficient cells
Arnab Ray Chaudhuri et al.
NATURE (2016)
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Serena Nik-Zainal et al.
NATURE (2016)
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
Yi Du et al.
NATURE MEDICINE (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Yves Pommier et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Expression of ADP-ribosyltransferase 1 Is Associated with Poor Prognosis of Glioma Patients
Zhen Li et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Increased global transcription activity as a mechanism of replication stress in cancer
Panagiotis Kotsantis et al.
NATURE COMMUNICATIONS (2016)
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Junko Murai et al.
ONCOTARGET (2016)
Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets
Claire E. Knezevic et al.
CELL CHEMICAL BIOLOGY (2016)
DNA Replication Stress as a Hallmark of Cancer
Morgane Macheret et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 10 (2015)
Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation
Idun Dale Rein et al.
CELL CYCLE (2015)
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study
Robert L. Coleman et al.
GYNECOLOGIC ONCOLOGY (2015)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Mechanistic Dissection of PARP1 Trapping and the Impacton In Vivo Tolerability and Efficacy of PARP Inhibitors
Todd A. Hopkins et al.
MOLECULAR CANCER RESEARCH (2015)
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System
Karen E. Parrish et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function
Felix Y. Feng et al.
MOLECULAR CELL (2015)
Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance
Peter Bai
MOLECULAR CELL (2015)
Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1
Sebastian Eustermann et al.
MOLECULAR CELL (2015)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
Whole-genome characterization of chemoresistant ovarian cancer
Ann-Marie Patch et al.
NATURE (2015)
REV7 counteracts DNA double-strand break resection and affects PARP inhibition
Guotai Xu et al.
NATURE (2015)
Exploiting replicative stress to treat cancer
Matthias Dobbelstein et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The PIN domain of EXO1 recognizes poly(ADP-ribose) in DNA damage response
Feng Zhang et al.
NUCLEIC ACIDS RESEARCH (2015)
Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer
Linda Henneman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Poly(ADP-Ribose) Mediates the BRCA2-Dependent Early DNA Damage Response
Feng Zhang et al.
CELL REPORTS (2015)
Pyrimidine Pool Disequilibrium Induced by a Cytidine Deaminase Deficiency Inhibits PARP-1 Activity, Leading to the Under Replication of DNA
Simon Gemble et al.
PLOS GENETICS (2015)
PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors
J. Farres et al.
CELL DEATH AND DIFFERENTIATION (2015)
Poly(ADP-Ribosyl) Glycohydrolase Prevents the Accumulation of Unusual Replication Structures during Unperturbed S Phase
Arnab Ray Chaudhuri et al.
MOLECULAR AND CELLULAR BIOLOGY (2015)
Myc and Ras oncogenes engage different energy metabolism programs and evoke distinct patterns of oxidative and DNA replication stress
Apolinar Maya-Mendoza et al.
MOLECULAR ONCOLOGY (2015)
An update on PARP inhibitors-moving to the adjuvant setting
Amir Sonnenblick et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma
Jara Majuelos-Melguizo et al.
ONCOTARGET (2015)
Trapping Poly(ADP-Ribose) Polymerase
Yuqiao Shen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
Ahrum Min et al.
BREAST CANCER RESEARCH (2015)
Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
Ilirjana Bajrami et al.
CANCER RESEARCH (2014)
Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment
Kishan A. T. Naipal et al.
CLINICAL CANCER RESEARCH (2014)
PTIP associates with Artemis to dictate DNA repair pathway choice
Jiadong Wang et al.
GENES & DEVELOPMENT (2014)
An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer
Monjri M. Shah et al.
GYNECOLOGIC ONCOLOGY (2014)
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
Liufu Deng et al.
IMMUNITY (2014)
PARP Inhibitors as P-glyoprotein Substrates
Denise Lawlor et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Transcriptional Roles of PARP1 in Cancer
Matthew J. Schiewer et al.
MOLECULAR CANCER RESEARCH (2014)
Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP
Olivia S. Chao et al.
MOLECULAR CANCER RESEARCH (2014)
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Junko Murai et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F. Liu et al.
LANCET ONCOLOGY (2014)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan Ledermann et al.
LANCET ONCOLOGY (2014)
Causes and consequences of replication stress
Michelle K. Zeman et al.
NATURE CELL BIOLOGY (2014)
PARG is dispensable for recovery from transient replicative stress but required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress
Giuditta Illuzzi et al.
NUCLEIC ACIDS RESEARCH (2014)
PARP-1 Expression is Increased in Colon Adenoma and Carcinoma and Correlates with OGG1
Tomasz Dziaman et al.
PLOS ONE (2014)
BRCA1 haploinsufficiency for replication stress suppression in primary cells
Shailja Pathania et al.
NATURE COMMUNICATIONS (2014)
Genome-wide transcriptome profiling of homologous recombination DNA repair
Guang Peng et al.
NATURE COMMUNICATIONS (2014)
Insights into PARP Inhibitors' Selectivity Using Fluorescence Polarization and Surface Plasmon Resonance Binding Assays
Gianluca Papeo et al.
JOURNAL OF BIOMOLECULAR SCREENING (2014)
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
Kirsten M. Timms et al.
BREAST CANCER RESEARCH (2014)
Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition
Junko Murai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
E. H. Lips et al.
BRITISH JOURNAL OF CANCER (2013)
Function of BRCA1 in the DNA Damage Response Is Mediated by ADP-Ribosylation
Mo Li et al.
CANCER CELL (2013)
53BP1 Mediates Productive and Mutagenic DNA Repair through Distinct Phosphoprotein Interactions
Elsa Callen et al.
CELL (2013)
ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA
Luis Ignacio Toledo et al.
CELL (2013)
BMN673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
Yuqiao Shen et al.
CLINICAL CANCER RESEARCH (2013)
Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue
M. Salemi et al.
EUROPEAN JOURNAL OF HISTOCHEMISTRY (2013)
Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival
Alex Gan et al.
HUMAN PATHOLOGY (2013)
Variations in the mRNA expression of poly(ADP-ribose) polymerases, poly(ADP-ribose) glycohydrolase and ADP-ribosylhydrolase 3 in breast tumors and impact on clinical outcome
Ivan Bieche et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP-ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells
Xiaoxing Feng et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer
Elena Castro et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Louise J. Barber et al.
JOURNAL OF PATHOLOGY (2013)
PARP-1 and gene regulation: Progress and puzzles
W. Lee Kraus et al.
MOLECULAR ASPECTS OF MEDICINE (2013)
RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection
J. Ross Chapman et al.
MOLECULAR CELL (2013)
A Cell Cycle-Dependent Regulatory Circuit Composed of 53BP1-RIF1 and BRCA1-CtIP Controls DNA Repair Pathway Choice
Cristina Escribano-Diaz et al.
MOLECULAR CELL (2013)
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen K. Sandhu et al.
LANCET ONCOLOGY (2013)
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth et al.
NATURE (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Evidence for APOBEC3B mutagenesis in multiple human cancers
Michael B. Burns et al.
NATURE GENETICS (2013)
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers
Steven A. Roberts et al.
NATURE GENETICS (2013)
Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition
Matteo Berti et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2013)
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer
S. Postel-Vinay et al.
ONCOGENE (2013)
A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity
Stephen J. Pettitt et al.
PLOS ONE (2013)
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
Neil Johnson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
53BP1 Regulates DSB Repair Using Rif1 to Control 5′ End Resection
Michal Zimmermann et al.
SCIENCE (2013)
PARG dysfunction enhances DNA double strand break formation in S-phase after alkylation DNA damage and augments different cell death pathways
H. Shirai et al.
CELL DEATH & DISEASE (2013)
Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation
WooKee Min et al.
NATURE COMMUNICATIONS (2013)
Visualization of poly(ADP-ribose) bound to PARG reveals inherent balance between exo- and endo-glycohydrolase activities
Eva Barkauskaite et al.
NATURE COMMUNICATIONS (2013)
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors
Janneke E. Jaspers et al.
CANCER DISCOVERY (2013)
Structural implications for selective targeting of PARPs
Jamin D. Steffen et al.
FRONTIERS IN ONCOLOGY (2013)
Beyond DNA repairs additional functions of PARP-1 in cancer
Alice N. Weaver et al.
FRONTIERS IN ONCOLOGY (2013)
Selective Small Molecule Inhibition of Poly(ADP-Ribose) Glycohydrolase (PARG)
Kristin E. Finch et al.
ACS CHEMICAL BIOLOGY (2012)
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
V. Abkevich et al.
BRITISH JOURNAL OF CANCER (2012)
A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2
Katharina Schlacher et al.
CANCER CELL (2012)
Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
Nasim Mavaddat et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2012)
HER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA Repair
Somaira Nowsheen et al.
CANCER RESEARCH (2012)
PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma
J. Chad Brenner et al.
CANCER RESEARCH (2012)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1
Songmin Ying et al.
CANCER RESEARCH (2012)
Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
Tatiana Popova et al.
CANCER RESEARCH (2012)
Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells
Catherine Fathers et al.
CELL CYCLE (2012)
Overexpression of chromatin assembly factor-1 p60, poly(ADP-ribose) polymerase 1 and nestin predicts metastasizing behaviour of oral cancer
Massimo Mascolo et al.
HISTOPATHOLOGY (2012)
Linking abnormal mitosis to the acquisition of DNA damage
Neil J. Ganem et al.
JOURNAL OF CELL BIOLOGY (2012)
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
Stan B. Kaye et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
DNA breaks and chromosome pulverization from errors in mitosis
Karen Crasta et al.
NATURE (2012)
The DNA damage response and cancer therapy
Christopher J. Lord et al.
NATURE (2012)
Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors
Elisabet Wahlberg et al.
NATURE BIOTECHNOLOGY (2012)
Structure of mammalian poly(ADP- ribose) glycohydrolase reveals a flexible tyrosine clasp as a substrate-binding element
In-Kwon Kim et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2012)
Topoisomerase I poisoning results in PARP-mediated replication fork reversal
Arnab Ray Chaudhuri et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Structural Basis for DNA Damage-Dependent Poly(ADP-ribosyl)ation by Human PARP-1
Marie-France Langelier et al.
SCIENCE (2012)
Structure and mechanism of a canonical poly(ADP-ribose) glycohydrolase
Mark S. Dunstan et al.
NATURE COMMUNICATIONS (2012)
Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
Lauren Averett Byers et al.
CANCER DISCOVERY (2012)
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Yasir H. Ibrahim et al.
CANCER DISCOVERY (2012)
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Ashish Juvekar et al.
CANCER DISCOVERY (2012)
Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
Nicolai J. Birkbak et al.
CANCER DISCOVERY (2012)
Synthetic Lethality of Cohesins with PARPs and Replication Fork Mediators
Jessica L. McLellan et al.
PLOS GENETICS (2012)
Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity
D. J. Gallagher et al.
ANNALS OF ONCOLOGY (2011)
PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy
Pawel Domagala et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Nucleotide Deficiency Promotes Genomic Instability in Early Stages of Cancer Development
Assaf C. Bester et al.
CELL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Barbara Norquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Collisions between Replication and Transcription Complexes Cause Common Fragile Site Instability at the Longest Human Genes
Anne Helmrich et al.
MOLECULAR CELL (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon et al.
LANCET ONCOLOGY (2011)
Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells
M. Fenech et al.
MUTAGENESIS (2011)
The structure and catalytic mechanism of a poly(ADP-ribose) glycohydrolase
Dea Slade et al.
NATURE (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress
Claudia Lukas et al.
NATURE CELL BIOLOGY (2011)
Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate
Cecilia E. Strom et al.
NUCLEIC ACIDS RESEARCH (2011)
PARG is recruited to DNA damage sites through poly(ADP-ribose)- and PCNA-dependent mechanisms
Oliver Mortusewicz et al.
NUCLEIC ACIDS RESEARCH (2011)
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
Anand G. Patel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Deletion of the nuclear isoform of poly(ADP-ribose) glycohydrolase (PARG) reveals its function in DNA repair, genomic stability and tumorigenesis
WooKee Min et al.
CARCINOGENESIS (2010)
53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Samuel F. Bunting et al.
CELL (2010)
Immunity, Inflammation, and Cancer
Sergei I. Grivennikov et al.
CELL (2010)
Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
Asima Mukhopadhyay et al.
CLINICAL CANCER RESEARCH (2010)
Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
Panagiotis A. Konstantinopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)-Ribose Polymerase Inhibitors
Jurgen Veeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic
Dana V. Ferraris
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
Peter Bouwman et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination
Helen E. Bryant et al.
EMBO JOURNAL (2009)
Radiation-induced mitotic catastrophe in PARG-deficient cells
Jean-Christophe Ame et al.
JOURNAL OF CELL SCIENCE (2009)
Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and-2 Mutant Tumors
Philip Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA
Kazuto Sugimura et al.
JOURNAL OF CELL BIOLOGY (2008)
4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
Keith A. Menear et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Wataru Sakai et al.
NATURE (2008)
Resistance to therapy caused by intragenic deletion in BRCA2
Stacey L. Edwards et al.
NATURE (2008)
PARP inhibition versus PARP-1 silencing:: different outcomes in terms of single-strand break repair and radiation susceptibility
Camille Godon et al.
NUCLEIC ACIDS RESEARCH (2008)
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites
Jean-Francois Haince et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase
Anna E. O. Fisher et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
Huw D. Thomas et al.
MOLECULAR CANCER THERAPEUTICS (2007)
PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways
Minli Wang et al.
NUCLEIC ACIDS RESEARCH (2006)
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition
Nuala McCabe et al.
CANCER RESEARCH (2006)
BRCA1 promoter methylation predicts adverse ovarian cancer prognosis
Jing Wang Chiang et al.
GYNECOLOGIC ONCOLOGY (2006)
Parp-1 protects homologous recombination from interference by Ku and ligase IV in vertebrate cells
H Hochegger et al.
EMBO JOURNAL (2006)
Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair
HE Bryant et al.
NUCLEIC ACIDS RESEARCH (2006)
Hypoxia-induced down-regulation of BRCA1 expression by E2Fs
RS Bindra et al.
CANCER RESEARCH (2005)
Gallotannin inhibits the expression of chemokines and inflammatory Cytokines in A549 cells
K Erdèlyi et al.
MOLECULAR PHARMACOLOGY (2005)
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
J Bartkova et al.
NATURE (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
VG Gorgoulis et al.
NATURE (2005)
Poly(ADP-ribose) glycohydrolase as a target for neuroprotective intervention:: assessment of currently available pharmacological tools
J Falsig et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality
DW Koh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks
YG Yang et al.
ONCOGENE (2004)
Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein
M Lomonosov et al.
GENES & DEVELOPMENT (2003)
PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase
CM Simbulan-Rosenthal et al.
ONCOGENE (2003)
A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage
SF El-Khamisy et al.
NUCLEIC ACIDS RESEARCH (2003)
Spatial and temporal cellular responses to single-strand breaks in human cells
S Okano et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: A mechanism for oncogene-induced genetic instability
O Vafa et al.
MOLECULAR CELL (2002)
Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase
AW White et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
